Simulations Plus (NASDAQ:SLP) Shares Down 8% - Time to Sell?

Shares of Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report) traded down 8% on Thursday . The company traded as low as $33.22 and last traded at $33.02. 108,838 shares traded hands during trading, a decline of 58% from the average session volume of 258,353 shares. The stock had previously closed at $35.90.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. William Blair reissued an "outperform" rating on shares of Simulations Plus in a report on Wednesday, January 8th. StockNews.com cut shares of Simulations Plus from a "hold" rating to a "sell" rating in a report on Monday, November 4th. Stephens started coverage on shares of Simulations Plus in a report on Friday, November 15th. They set an "overweight" rating and a $39.00 price objective on the stock. Finally, KeyCorp raised their target price on shares of Simulations Plus from $35.00 to $37.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $49.40.

Simulations Plus Price Performance

The firm has a market capitalization of $638.26 million, a PE ratio of 79.43 and a beta of 0.83. The business's 50-day moving average price is $31.69 and its 200-day moving average price is $32.19.

Insider Transactions at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $31.76, for a total value of $635,200.00. Following the transaction, the director now directly owns 3,442,584 shares in the company, valued at $109,336,467.84. This trade represents a 0.58 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 19.40% of the company's stock.

Hedge Funds Weigh In On Simulations Plus

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Public Employees Retirement System of Ohio raised its stake in shares of Simulations Plus by 58.6% during the 4th quarter. Public Employees Retirement System of Ohio now owns 41,692 shares of the technology company's stock worth $1,163,000 after buying an additional 15,399 shares during the last quarter. Millennium Management LLC raised its stake in shares of Simulations Plus by 200.7% during the 4th quarter. Millennium Management LLC now owns 44,841 shares of the technology company's stock worth $1,251,000 after buying an additional 29,929 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Simulations Plus by 4.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,103 shares of the technology company's stock worth $254,000 after buying an additional 380 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Simulations Plus by 7,753.3% during the 4th quarter. Janus Henderson Group PLC now owns 542,899 shares of the technology company's stock worth $15,141,000 after buying an additional 535,986 shares during the last quarter. Finally, Deutsche Bank AG raised its stake in shares of Simulations Plus by 52.9% during the 4th quarter. Deutsche Bank AG now owns 14,916 shares of the technology company's stock worth $416,000 after buying an additional 5,160 shares during the last quarter. 78.08% of the stock is currently owned by hedge funds and other institutional investors.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.